Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, opens a panel discussion surrounding the treatment pathways for patients diagnosed with early breast cancer. Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC: ...

IPF diagnosis relies on clinical evaluation, HRCT, and occasionally lung biopsy to identify usual interstitial pneumonia patterns. The average time to IPF diagnosis can be delayed up to two years due ...

Plus Therapeutics will present ReSPECT-LM trial results and host a symposium on leptomeningeal metastases at the SNO/ASCO conference. Announcement of the oral presentation of ReSPECT-LM clinical trial ...

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today ...

Like their causative mutations, pathophysiology and natural history, the clinical presentation of inborn errors of immunity (IEI) varies widely. Nevertheless, some features, above all recurrent and/or ...

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the ...

Diagnosis of ankylosing spondylitis/axial spondyloarthritis (AS/axSpA) at an early stage is not a simple task and is often missed or markedly delayed, especially in a primary care setting, unless the ...

6. Presentation Title: Phase 2 trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 ...

ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and efficacy signal, supporting continued Phase 2 enrollment and investigation MRI ...

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used ...